

Probiotics and Traditional Fermented Foods: The Eternal Connection (Mini-Review)

Adel M. Mahasneh* and Muna M. Abbas

Department of Biological Sciences, University of Jordan, Amman 11942, Jordan

Abstract

Interactions of probiotic bacteria with the host and the impact of this interaction continue to fascinate microbial biotechnologists. Highlights of these influences of bacteria on human systems have been obtained from comparisons using germ free and conventional experimental animals. Where applied, outcomes and therapeutic uses are involved. There is a need to diversify the sources of isolation of probiotic bacteria to include fermented traditional foods of different societies. This approach invites more comprehensive research on different models to prove probiotics efficacy in a very well-defined patient groups pertaining to varied geographical locations, different ethnic communities and cultural values. Such invitation, no doubt, is motivated by the pressing need to develop and design alternatives to drugs causing bacterial resistance and risky side effects as well as complimentary treatments for other non-microbial diseases.

الملخص

إن تفاعل المحسنات الحيوية البكتيرية مع العائل وأثر ذلك كان وما زال يثير إعجاب علماء التقنيات الحيوية للأحياء الدقيقة وإن الآثار المميزة لهذه البكتيريا قد تم توثيقها من خلال دراسات مقارنة على حيوانات مخبرية. وأشارت نتائج هذه المقارنات لضرورة تنوع مصادر عزل هذه المحسنات الحيوية البكتيرية لتشمل أغذية مخمرة تقليدية لمجتمعات متباينة. ومن المؤمل أن تؤدي هذه المقارنات لدراسات شاملة على نماذج مختلفة لإثبات فعالية هذه المحسنات على مجموعات المرضى المحددة مكانياً وعرقياً ومع قيمها الحضارية. ولا شك بأن هذا التوجه سيتعزز بالحاجة الماسة لتطوير وتصميم بدائل لعقارات تؤدي لظهور المقاومة في البكتيريا إضافة للأعراض الجانبية كما يمكن أن تكون هذه المحسنات البكتيرية مكملة في معالجة أمراض غير بكتيرية.

© 2010 Jordan Journal of Biological Sciences. All rights reserved

Keywords: Probiotics, Traditional foods, Microbiota, Host-probiotic interactions.

1. Introduction

"Let food be thy medicine and medicine be thy food" as Hippocrates said, is the principle of today (Suvarna and Boby, 2005). Probiotics are one of the functional foods that link diet and health. Probiotics "For Life" are living, health-promoting microbial food ingredients that have a beneficial effect on humans (Chuayana *et al.*, 2003).

The concept of probiotics have been first proposed by Nobel Prize winner Russian scientist Elie Metchnikoff, who suggested that the long life of Bulgarian peasants resulted from their utilization of fermented milk products (Mercenier *et al.*, 2002; Chuayana *et al.*, 2003; Tannock, 2003). Metchnikoff thought that when the fermented milk products were consumed, the fermenting *Lactobacillus* positively influenced the microflora of the gut, decreasing toxic microbial activities there (Mercenier *et al.*, 2002; Chuayana *et al.*, 2003).

As a result of more investigations in the probiotic field, its concept has been expanded to include bacteria from intestinal origin beside those bacteria isolated from fermented dairy products (Zeng *et al.*, 2010). And we believe now that traditionally fermented foods are the untapped source for a wide variety of beneficial probiotic microorganisms.

Lactic acid bacteria (LAB) are the most common type of microorganisms used as probiotics. Strains of the genera *Lactobacillus*, *Bifidobacterium* (Yateem *et al.*, 2008) and *Enterococcus* (Ljungh and Wadström, 2006) are the most widely used and commonly studied probiotic bacteria. The yeast *Saccharomyces boulardii* has also been studied as probiotics (Ljungh and Wadström, 2006).

All of these microorganisms have been considered as probiotics according to several criteria such as their total beneficial effect on the host, being non-pathogenic (Suvarna and Boby, 2005), and their ability to survive transit through the gastrointestinal (GI) tract (Saito, 2004; Crittenden *et al.*, 2005; Liang and Shah, 2005).

Probiotic bacteria actions include: adherence and colonization of the host gut (Sanders, 2003), suppression of growth and invasion by pathogenic bacteria (Reid and

* Corresponding author. amahasneh@ju.edu.jo.

Burton, 2002), production of antimicrobial substances such as bacteriocins (Nowroozi *et al.*, 2004), improvement of intestinal barrier function, and stimulation of host immunity (Tannock, 2003).

Evidence from *in vitro* systems, animal models and humans suggests that the therapeutic use of probiotics has been considered very successful in the cases of lactose intolerance (Suvarna and Boby, 2005), inflammatory bowel disease (Daniel *et al.*, 2006), colon cancer, *Helicobacter pylori* infection (Ouwehand *et al.*, 2002), reduction of allergy, irritable bowel syndrome (Ljungh and Wadström, 2006), and certain diarrheal disease including antibiotic-associated diarrhea in adults, travelers' diarrhea, and diarrheal diseases in young children (Reyed, 2007). Additionally, probiotics may improve intestinal mobility and relieve constipation, especially in seniors (Ouwehand *et al.*, 2002; Crittenden *et al.*, 2005). They also reduce the cholesterol levels in serum (Liong and Shah, 2005) and no doubt many other benefits are there to be found by diligent research efforts.

Nowadays, probiotics are available in a variety of food products, dietary supplements (Parvez *et al.*, 2006) and drugs (Sanders, 2003). In the United States, food products containing probiotics are almost exclusively dairy products - fluid milk and yoghurt- due to the historical association of lactic acid bacteria with fermented milk (Schillinger, 1999). The most frequently used bacteria in these products include *Lactobacillus* and *Bifidobacterium* (Sanders, 2003).

Probiotics are commonly not long-term colonizers of the GI tract, although they can adhere temporarily to the epithelium (Bezkorovainy, 2001). Instead, they may divide very slowly in the intestine, while remaining metabolically active (Marco *et al.*, 2006). Therefore, daily consumption of these bacteria is probably the best way to maintain their effectiveness (Champs *et al.*, 2003).

Isolation and characterization of novel strains of lactic acid bacteria from uninvestigated niche could have the dual advantage of revealing taxonomic characteristics and obtaining strains with interesting new functional traits that may be useful for probiotic application (Ortu *et al.*, 2007). Among resources of probiotic bacteria are traditional fermented foods which vary according to societies and social habits of dieting (Reddy *et al.*, 2007).

2. Present status of the art

Searching literature demonstrates the rapid growth of probiotics research with most published articles dates after 2003 (Reid *et al.*, 2006). The type of research is being extended to include discovering events taking place at the interface between mucosal lining and microbiota, links between probiotics use and effects at distant body sites. Applications in the fields of allergy, inflammation,

cardiovascular diseases and cancers are top priority targets hoping to benefit mankind, the emphasis being upon therapy rather than health improvements only. Recent research results were successful in using certain probiotic bacteria as a delivery system of endostatin for cancer gene therapy (Hu *et al.*, 2009). The biological activity of some probiotics is attributed to fermentation end products including among others organic acids, CO₂, H₂O₂, diacetyl, and bacteriocins (Müller *et al.*, 2009; Sanahan, 2010). In the majority of cases, this biological activity is a combination of all these factors (Todorov and Dicks, 2005). Probiotic induced-pathogen inhibitor may provide significant protection against pathogen spread in the gastrointestinal tract leading to enhanced human health (Collado *et al.*, 2007a) through inhibition, displacement or competition with the pathogen (Gueimonde *et al.*, 2006). Among the most studied bacteria as a probiotic included mainly isolates of the genera *Lactobacillus* and *Bifidobacterium*. Other bacteria of less potential as probiotics are isolates of the genus *Bacillus* such as *Bacillus subtilis*, *Bacillus clausii*, *Bacillus pumilus* and *Bacillus coagulans* (Hong *et al.*, 2005; Patel *et al.*, 2009). Reports claiming that probiotics use strengthened immune system, and helped in combating allergies, excessive alcohol intake and other diseases (Nichols, 2007; Sanders, 2003) encouraged researchers to search for novel probiotic bacteria in traditionally fermented foods which is usually linked to good health of people who consume such foods regularly (Salminen *et al.*, 1998).

According to Reid, *et al.*, 2006, the understanding of probiotic microorganisms has expanded in the last 20 years after incepting the term in research circles. The term now implicates exact speciation of the microorganism, safe and effective use of probiotic formulations, exhibition of health and or therapeutic benefits on experimental models and probably volunteers and finally safe manufacture and retail. Unfortunately, these requirements are not fully observed worldwide, resulting in marketing too many of the so-called probiotics that do not meeting the proper criteria of a true probiotic. Table 1 presents few examples of bacterial probiotic strains which belong mainly to species of the genera *Lactobacillus* and *Bifidobacterium* with exceptions pertaining to *Escherichia coli* and the yeast *Saccharomyces cerevisiae*. Such information provide us with substantial evidence that in the last decade probiotics are beginning to be a convincing complimentary rout to traditional drug-based therapies. This trend, will with no doubt pave the way for more sophisticated approaches to develop genetically modified microorganisms which harbour new traits in constructed probiotics for special therapeutic purposes; such thoughts were entertained by Lartigue *et al.*, (2007) in his article about genome transplantation in bacteria.

Table 1. Probiotic microorganisms exhibiting positive clinical responses.

Strain	Probiotic clinical response
<i>Lactobacillus rhamnosus</i> GG	Adhesion displacement of several pathogens (Collade <i>et al.</i> , 2007b).
<i>Bifidobacterium animalis</i> BB12	Prevention and treatment of diarrhea (Weizman <i>et al.</i> , 2005).
<i>Bifidobacterium infantis</i> 35624	Relieve abdominal pain (O'Mahony <i>et al.</i> , 2005).
<i>Lactobacillus paracasei</i> LP-33	Relieve of allergic rhinitis (Wang <i>et al.</i> , 2004a).
<i>Lactobacillus acidophilus</i> La5	<i>Helicobacter pylori</i> inhibition (Wang <i>et al.</i> , 2004b).
<i>Lactobacillus reuteri</i> ATCC 55730	Production of CD4- positive T- lymphocytes (Valeur <i>et al.</i> , 2004).
<i>Bifidobacterium longum</i> BL1	Serum cholesterol reduction (Xiao <i>et al.</i> , 2003).
<i>Saccharomyces cerevisiae</i> Lyo	Reduced diarrhea (Kurugol and Koturoglu, 2005).
<i>Escherichia coli</i> Nissle 1917	Colitis treatment (Tromm <i>et al.</i> , 2004)
<i>Lactobacillus plantarum</i> LP31	Inhibition of food pathogens (Müller <i>et al.</i> , 2009).
<i>Bifidobacterium longum</i>	Antitumor effect (Hu <i>et al.</i> , 2009).
<i>Lactobacillus salivarius</i> UCC118	Colon cancer reduction in mice (O'Mahony <i>et al.</i> , 2001).
<i>Lactobacillus buchneri</i> P2	Serum cholesterol reduction (Zeng <i>et al.</i> , 2010).
<i>Lactobacillus casei</i>	Reduction of bladder cancer (Ohashi <i>et al.</i> , 2002).

3. Bioprospecting for probiotics in traditional fermented foods

The majority of infectious diseases caused by pathogenic bacteria and fungi represent a real challenge for current efforts to combat it through chemical and pharmacological research (Sanders *et al.*, 2003). Rapid emergence of antibiotic resistance by many pathogens, along with increased toxicity of in field antibiotics prompts the continuous search and development of new anti-infective and antipathogenic materials (Sleator and Hill, 2006). Antipathogenic and probiotic bacteria would be the corner-stone in the search for new and effective alternative to traditional prophylactic means in a variety of clinical cases and settings (Sleator and Hill, 2008). In the last decade, it was observed that the selection of probiotics is based mainly on their ability to adhere and colonize the gastrointestinal epithelia and to compete with pathogens for binding sites and nutrients (Collado *et al.*, 2007a; Ouwehand and Salminen, 2003). The functional activity of probiotics have been associated with managing the diarrheal and gastrointestinal infections by probiotics strains of different species of Lactics isolated mainly from fermented dairy products and related sources available in the western hemisphere (D'Souza *et al.*, 2002). In addition, there is ample evidence suggesting the use of probiotics to treat and prevent urinary tract infection (Velraeds *et al.*, 1998), rotavirus diarrhea (Szajewska *et al.*, 2001), recurrence of certain cancers (Ohashi *et al.*, 2002), and reduction of allergies (Gill and Guarner, 2004) and recently, probiotic prophylaxis against asthma and eczema is being entertained (Sleator and Hill, 2008).

Most research articles pertaining to the aforementioned observations were dependent upon bacterial probiotics originating mainly from fermented dairy products and to less extent from human body indigenous microflora such as vaginal isolates or infants faeces (Reid, 2005). While the probiotic market is growing rapidly, it becomes eminent to diversify our sources in the search for new and

novel probiotic microorganisms. This trend is encouraged by remarks stating that using different strains from different sources present interesting situations since differences between strains of the same species do exist (Reid, 2005; Weizman *et al.*, 2005).

4. Oriental sources for probiotic strain selection

With the increased data about benefits of probiotics for human health and treatment and since most isolated and patented strains are of western origin, it is greatly inviting to try and isolate such probiotics from the untapped source exemplified by a wide variety of different fermented foods of the orient (Table 2). For example, Keshik which is a Jordanian traditional fermented food made up of barboiled dried wheat and butter milk is of interest (Tamime and O'Connor, 1995). The product is similar to Tarhana (Turkish traditional fermented food) which proved to be a rich source of probiotic Lactic acid bacteria (Sengun, 2009). Among other potential foods also is the fermented eggplant (locally named Makdoos) made up of baby Aubergine stuffed with ground wall-nut, garlic, parsley and fermented in olive oil. Jameed which is solar-dried curd of sheep or goat naturally-fermented milk prepared and used traditionally by Jordanian Beduins (the old desert dwellers) is another unique source of probiotic bacteria. In a preliminary screen (un-published data) we were able to isolate a wide selection of lactic acid bacteria from these foods to be tested further for their suitability and unique probiotic properties. Recently, probiotic lactic acid bacteria have been isolated from unpasteurized natural camel milk with superior probiotic characteristics (Yateem *et al.*, 2008; Khedid *et al.*, 2009). These are just few examples of traditional foods in Jordan as part of the Middle East and many other countries of the orient would probably be richer especially traditional fermented foods of South East Asia and India, which invites more research in this direction. The long shelf-life of such traditional foods could probably indicate the presence of

antimicrobial compounds among other characteristics exhibited by the indigenous bacteria which makes it a good probiotic candidate. Linking this to the increased

consumer demand for natural and additive free foods would definitely maximize the interest in search for new sources of probiotic strains (Müller *et al.*, 2009).

Table 2. Some oriental traditional foods of East Mediterranean countries including Jordan.

Traditional food	Ingredients/ natural fermentation
Aubergine Makdoos	Aubergine, wall-nuts, garlic, parsley, salt fermented in olive oil.
Green pepper Makdoos	Sweet green pepper, shredded tomato, parsley, salt garlic fermented in water or olive oil.
Pickled Green or Black Olives	Olives, salt, water fermented or pickled in olive oil.
Vine leaves	Vine leaves, pickled or packed to ferment naturally.
Keshik	Boiled wheat, thick curd of goat or sheep yoghurt or fermented milk, salt subjected to solar drying where slow fermentation takes place.
Jameed	Goat or sheep thick yoghurt curd, salt and then solar dried where slow fermentation improve the taste.
Tarhana	Dried mixture of cracked wheat yoghurt or fermented milk.
Turkish Tarhana	Cracked wheat or flour, yoghurt and vegetables fermented and then dried.
Cyprus Tarhana	Cracked wheat and fermented milk flavoured with bay leaf, thyme and fennel seed.
Shatta	Ground dried miniature chilies fermented in salt water and vegetable oil.

5. Probiotic delivery and persistence:

In order to secure full functionality of a probiotic, an efficient delivery system, in vivo survival and clear clinical efficacy must be met (Doleyres and Lacroix, 2005). In this context, it is implicated that increasing the stresses' tolerance level of the probiotic microorganism is of utmost importance (Sheehan *et al.*, 2007). The novel thoughts of improving probiotic functions may be seen through modifying the strain tolerance to different stresses on the genetic level. This thought has been tested using some probiotic strains of *Bifidobacterium breve* and *Lactobacillus salivarius* (Sheehan *et al.*, 2006), but further investigations are needed such as interference with the ability of a probiotic microorganism to enhance its compatible solutes productivity which is another approach of arming probiotics against different stresses (Termont *et al.*, 2006), an area which also needs further exploration in the quest for the best probiotic formulations. The third prospective approach involves what is referred to as designer probiotics i.e. which are basically tailored-probiotics that would be very specific in targeting pathogens or intoxications where by doing this a pronounced prophylactic and therapeutic effects are realized (Laurel and Berger, 2005; Paton *et al.*, 2005). Genetic engineering has been thought of as a useful approach for the design of probiotic bacteria that counteract the symptoms of genetic and age related diseases (Saier and Mansour, 2005). In combination therapy, components of pathogenic and nonpathogenic food-related bacteria are currently being evaluated as candidates for oral vaccines (Amdekar *et al.*, 2009; Gill and Prasad, 2008; Collado *et al.*, 2007b). It is believed now that as our knowledge of microbial variations is

refined, tailoring of human associated microorganisms is rational and may lead to remodeling of their functions (Predis and Versalovic, 2009). Roos *et al.*, (2010) reported improved humoral immune response against *E. coli* and bovine herpes vaccines in lambs through feeding with probiotic *B. cereus* and *Saccharomyces boulardii* strains.

6. Side effects and risks:

Some microorganisms have a long history of use as probiotics without causing illnesses in consumers. However, some probiotics safety has not been fully studied and understood scientifically. More information is especially needed on how safe they are for infants, children, old people and those with compromised immune systems.

Probiotics side effects, if they exist, would probably be mild digestive disturbances including gas and bloating. More serious contraindications have been observed in some incidences. Probiotics might in theory cause infections that need antibiotic treatments especially with people underlying health problems. They may also cause unhealthy metabolic activities i.e. too much stimulation of the immune system or even gene transfer among cells (Nerstedt, 2007).

Side effects and unsubstantiated claims are possible with prophylactic agents including probiotics. Probiotics are microorganisms, and we know the unpredictability of microorganisms in terms of how it will react to the existing or indigenous microbiota located in the target host. Gould and Shrot (2008) pointed out that particular illnesses such as post-antibiotic diarrhoea are very responsive to probiotic treatment. However, they emphasize that many studies on humans have been disappointing although so

many of therapeutic potentials of probiotics still need great deal of substantiation before being recommended for medicinal applications. With these in mind, probiotics might be considered as one facet in a patient's health maintenance strategy. To conclude, we would say that since each human family and each individual in that family harbour a different combination of gut microflora, there may be some genetic propensities for and against certain probiotic strains. More investigations are needed to find out which group may benefit from which probiotic candidates and probably the source-effect of that probiotic microorganism. Further along the same concept, it is usually accepted to say that many studies of probiotics are carried on experimental animals rather than human subjects where lab results and animal studies cannot always be generalized to results in humans. In this context, it is observed that a single bacterial strain colonizing the gut of a gnotobiotic usually reaches a much higher counts than it does in a conventional animal, where the bacteria is faced with competition from others (Tannock, 2004). It is also noted that in the complex conventional ecosystem, the process of up and down regulation of host genes expression induced by different bacterial species vary tremendously with the presence of varying species and even strains (Hooper *et al.*, 2001).

7. Conclusion

Probiotics are receiving great deal of attention in different fields of microbial biotechnology applications including health improvement and therapeutic purposes. This necessitates further diversification of sources of isolation to include traditional fermented foods of different cultures and geographical settings. Further works are needed to elucidate the functional characteristics of probiotic microorganisms. Designer probiotic for specific treatment is also an emerging field of research which would strengthen the drive of using probiotics for the treatment of different ailments and human health improvements.

References:

- Amdekar S Dwivedi D Roy P Kushwah S and Singh V. 2009. Probiotics: multifarious oral vaccine against infectious traumas. *Immunol Med Microbiol.* **58**: 299-306.
- Bezkorovainy A. 2001. Probiotics: determinants of survival and growth in the gut. *Am J Clin Nutr.* **73**: 399S-405S.
- Champs CD Maroncle N Balestrino D Rich C and Forestier C. 2003. Persistence of colonization of intestinal mucosa by a probiotic Strain, *Lactobacillus casei* subsp. rhamnosus Lcr35, after oral consumption. *J Clin Microbiol.* **41**(3): 1270-1273.
- Chuayana Jr, EL Ponce CV Rivera MRB and Cabrera EC. 2003. Antimicrobial activity of probiotics from milk products. *Phil J Microbiol Infect Dis.* **32**: 71-74.
- Collado MC Meriluoto J and Salminen S. 2007a. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. *Lett Appl Microbiol.* **45**: 454-460.
- Collado MC Meriluoto J and Salminen S. 2007b. Development of new probiotics by strain combinations: is it possible to improve the adhesion to intestinal mucus. *J Dairy Sci.* **90**: 2710-2716.
- Crittenden R Bird AR Gopal P Henriksson A Lee YK and Playne MJ. 2005. Probiotic research in Australia, New Zealand and the Asia-Pacific Region. *Curr Pharmaceut Design.* **11**: 37-53.
- Daniel C Poiret S Goudercourt D Dennin V Leyer G and Pot B. 2006. Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. *Appl Environ Microb.* **72**: 5799-5805.
- Doleyres Y and Lacroix C. 2005. Technologies with free and immobilised cells for probiotic bifidobacteria production and protection. *Int Dairy J.* **15**: 973-988.
- D'Souza AL Rajkumar C Cooke J and Bulpitt CJ. 2002. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. *Br Med J.* **324**: 1361-1366.
- Gill HS and Guarner F. 2004. Probiotics and human health: a clinical perspective. *Postgrad Med J.* **80**: 516-526.
- Gill HS and Prasad J. 2008. Probiotics, immunomodulation, and health benefits. *Adv Exp Med Biol.* **606**: 423-454.
- Gould K and Shrot G. 2008. Probiotics and antibiotic-associated diarrhea-a logical flow? *J Antimicrob Chemother.* **61**: 761-761.
- Gueimonde M Jalonen L He F Hiramatsu M and Salminen S. 2006. Adhesion and competitive inhibition and displacement of human enteropathogens by selected lactobacilli. *Food Res Int.* **39**: 467-471.
- Hong HA Duc LH and Cutting SM. 2005. The use of bacterial spore formers as probiotics. *FEMS Microbiol Rev.* **29**: 813-835.
- Hooper LV Wong MH Thelin A Hansson L Falk PG and Gordon JI. 2001. Molecular analysis of commensal host-microbial relationships in the intestine. *Science.* **291**: 881-884.
- Hu B Kou L Li C Zhu LP Fan YR Wu ZW Wang JJ and Xu GX. 2009. *Bifidobacterium longum* as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth. *Cancer Gene Ther.* **16**: 655-663.
- Khedid K Faid M Mokhtari A Soulaymani A and Zinedine A. 2009. Characterization of lactic acid bacteria isolated from the one humped camel milk produced in Morocco. *Microbiol Res.* **164**: 81-91.
- Kurugol Z and Koturoglu G. 2005. Effects of *Saccharomyces boulardii* in children with acute diarrhea. *Acta Paediatr.* **94**: 44-47.
- Lartigue C Glass JI Alperovich N Pieper R Parmar PP Hutchison CA, III Smith HO and Venter JC. 2007. Genome transplantation in bacteria: changing one species to another. *Science.* **317**: 632-638.
- Laurel AL and Berger EA. 2005. An anti-HIV microbicide comes alive. *Proc Natl Acad Sci USA.* **102**: 12294-12295.
- Liong MT and Shah NP. 2005. Acid and bile tolerance and cholesterol removal ability of *Lactobacilli* strains. *J. Dairy Sci.* **88**: 55-66.

- Ljungh A and Wadström T. 2006. Lactic acid bacteria as probiotics. *Curr. Issues Intest. Microbiol.* **7**: 73-89.
- Marco ML Pavan S and Kleerebezem M. 2006. Towards understanding molecular modes of probiotic action. *Curr. Opin. Biotechnol.* **17**: 204-210.
- Mercenier A Pavan S and Pot P. 2002. Probiotics as biotherapeutic agents: Present knowledge and future prospects. *Curr. Pharmaceut. Design.* **8**: 99-110.
- Müller DM Carrasco MS Tonarelli GG and Simonetta AC. 2009. Characterization and purification of a new bacteriocin with a broad inhibitory spectrum produced by *Lactobacillus plantarum* lp 31 strain isolated from dry-fermented sausage. *J. Appl. Microbiol.* **106**: 2031-2040.
- Nersted A Nilsson EC Ohlson K Håkansson J Svensson LT Löwenadler B Svensson UK and Mahlapuu M. 2007. Administration of *Lactobacillus* evokes coordinated changes in the intestinal expression profile of genes regulating energy homeostasis and immune phenotype in mice. *Br. J. Nutr.* **97**: 1117-1127.
- Nichols AW. 2007. Probiotics and athletic performance: a systemic review. *Curr Sports Med Rep.* **6**: 269-273.
- Nowroozi J Mirzaii M and Norouzi M. 2004. Study of *Lactobacillus* as probiotic bacteria. *Iran J Publ Health.* **33**: 1-7.
- Ohashi Y Nakai S Tsukamoto T Masumori N Akaza H Miyanaga N Kitamura T Kawabe K Kotake T Kuroda M Naito S Koga H Saito Y Nomata K Kitagawa M and Aso Y. 2002. Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. *Urol Int.* **68**: 273-280.
- O'Mahony L McCarthy J Kelly P Hurley G Luo F Chen K O'Sullivan GC Kiely B Collins JK Shanahan F and Quigley EMM. 2005. *Lactobacillus* and *Bifidobacterium* in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. *Gastroenterology.* **128**: 541-551.
- O'Mahony L Feeney M O'Halloran S Murphy L Kiely B Fitzgibbon J Lee G O'Sullivan G Shanahan F and Collins JK. 2001. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. *Aliment Pharmacol Ther.* **15**: 1219-1225.
- Ortu S Felis GE Marzotto M Deriu A Molicotti P Sechi LA Dellaglio F and Zanetti S. 2007. Identification and functional characterization of *Lactobacillus* strains isolated from milk and Gioddu, a traditional Sardinian fermented milk. *Int. Dairy J.* **17**: 1312-1320.
- Ouwehand AC and Salminen S. 2003. *In vitro* adhesion assays for probiotics and their *in vivo* relevance: a review. *Microb Ecol Health Dis.* **15**: 175-184.
- Ouwehand AC Salminen S and Isolauri E. 2002. Probiotics: An overview of beneficial effects. *Antonie Leeuwenhoek.* **82**: 279-289.
- Parvez S Malik KA Kang S Ah and Kim HY. 2006. Probiotics and their fermented food products are beneficial for health. *J. Appl. Microbiol.* **100**: 1171-1185.
- Patel AK Ahire JJ Pawar SP Chaudhari BL and Chincholkar SB. 2009. Comparative accounts of probiotic characteristics of *Bacillus* spp. isolated from food wastes. *Food Res Int.* **42**: 505-510.
- Paton AW Jennings MP Morona R Wang H Focareta A Roddam LF and Paton JC. 2005. Recombinant probiotics for treatment and prevention of enterotoxigenic *Escherichia coli* diarrhea. *Gastroenterology.* **128**: 1219-1228.
- Preidis GA and Versalovic J. 2009. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. *Gastroenterology.* **136**: 2015-2031.
- Reddy KB Raghavendra PK Kumar BG Misra MC and Prapulla SG. 2007. Screening of probiotic properties of lactic acid bacteria isolated from Kanjika, and ayurvedic lactic acid fermented product: An *in-vitro* evaluation. *J Gen Appl Microbiol.* **53**: 207-213.
- Reid G Kim SO and Köhler GA. 2006. Selecting, testing and understanding probiotic microorganisms. *FEMS Immunol Med Microbiol.* **64(2)**: 149-157.
- Reid G. 2005. Colonization of the vagina and urethral mucosa. In: Nataro JP Cohen PS Mobley HLT and Weiser JN, editors. **Colonization of Mucosal Surfaces.** ASM Press, Washington, DC., pp. 431-448.
- Reid G and Burton J. 2002. Use of *Lactobacillus* to prevent infection by pathogenic bacteria. *Microb Infect.* **4**: 319-324.
- Reyed RM. 2007. Probiotics: A new strategies for prevention and therapy of diarrhea disease. *J. Appl. Sci. Res.* **3**: 291-299.
- Roos TB Tabeleão VC Dümmer LA Schwegler E Goulart MA Moura SV Corrêa MN Leite FBL and Gil-Turnes C. 2010. Effect of *Bacillus cereus* var. Toyoi and *Saccharomyces boulardii* on the immune response of sheep to vaccines. *Food Agric Immunol.* **21**: 1465-3443.
- Saier MH and Mansour NM. 2005. Probiotics and prebiotics in human health. *J Mol Microbiol Biotechnol.* **10**: 22-25.
- Saito T. 2004. Selection of useful probiotic lactic acid bacteria from the *Lactobacillus acidophilus* group and their applications to functional foods. *Anim. Sci. J.* **75**: 1-13.
- Salminen S Bouley C Boutron-Ruault MC Cummings JH Franck A Gibson GR Isolauri E Moreau MC Roberfroid M and Rowland I. 1998. Functional food science and gastrointestinal physiology and function. *Br J Nutr.* **80**: S147-S171.
- Sanahan F. 2010. Gut microbes: from bugs to drugs. *AM J Gastroenterol.* **105**: 275-279.
- Sanders ME. 2003. Probiotics: considerations for human health. *Nutr Rev.* **61**: 91-99.
- Sanders ME Morelli L and Tompkins TA. 2003. Spore formers as human probiotics: *Bacillus*, *Sporolactobacillus*, and *Brevibacillus*. *Compr. Rev. Food Sci. Food Safety.* **2**: 101-110.
- Schillinger U. 1999. Isolation and identification of lactobacilli from novel-type probiotic and mild yoghurts and their stability during refrigerated storage. *Int J Food Microbiol.* **47**: 79-87.
- Sengun I Neilsen D Karapinar M and Jakobsen M. 2009. Identification of lactic acid bacteria isolated from Tarhana, a

- traditional Turkish fermented food. *Int J Food Microbiol.* **135**: 105-111.
- Sheehan VM Sleator RD Fitzgerald GF and Hill C. 2006. Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of *Lactobacillus salivarius* UCC118. *Appl Environ Microbiol.* **72**: 2170-2177.
- Sheehan VM Sleator RD Fitzgerald GF and Hill C. 2007. Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic strain *Bifidobacterium breve* UCC2003. *Microbiology.* **153**: 3563-3571.
- Sleator RD and Hill C. 2006. Patho-biotechnology; using bad bugs to do good things. *Curr Opin Biotechnol.* **17**: 211-216.
- Sleator RD and Hill C. 2008. New frontiers in probiotic research. *Lett Appl Microbiol.* **46**: 143-147.
- Suvarna VC and Boby UV 2005. Probiotics in human health: A current assessment. *Curr. Sci.* **88**: 1744-1748.
- Szajewska H Kotowska M Mrukowicz JZ Armanska M and Kikolajczyk W. 2001. Efficacy of *Lactobacillus GG* in prevention of nosocomial diarrhoea in infants. *J Pediatr.* **138**: 361-365.
- Tamime A and O'Connor T. 1995. Kishk- A dried fermented milk/ cereal mixture. *Int Dairy J.* **5**: 109-128.
- Tannock GW. 2003. Probiotics: Time for a dose of realism. *Curr. Issues Intest. Microbiol.* **4**: 33-42.
- Tannock GW. 2004. A special fondness for Lactobacilli. *Appl Environ Microbiol.* **70**: 3189-3194.
- Termont S Vandenbroucke K Iserentant D Neiryck S Steidler L Remaut E and Rottiers P. 2006. Intracellular accumulation of trehalose protects *Lactococcus lactis* from freeze-drying damage and bile toxicity and increases gastric acid resistance. *Appl Environ Microbiol.* **72**: 7694-7700.
- Todorove SD and Dicks LMT. 2005. Characterization of bacteriocins produced by lactic acid bacteria isolated from spoiled black olives. *J. Basic Microbiol.* **45**: 312-322.
- Tromm A Niewerth U Khoury M Baestlein E Wilhelms G Schulze J and Stolte M. 2004. The probiotic *E. coli* strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial. *Z Gastroenterol.* **42**: 365-369.
- Valeur N Engel P Carbajal N Connolly E and Ladefoged K. 2004. Colonization and immunomodulation by *Lactobacillus reuteri* ATCC 55730 in the human gastrointestinal tract. *Appl Environ Microbiol.* **70**: 1176-1181.
- Velraeds MMC van der Belt B van der Mei HC Reid G and Busscher HJ. 1998. Interference in initial adhesion of uropathogenic bacteria and yeasts silicone rubber by a *Lactobacillus acidophilus* biosurfactant. *J Med Microbiol.* **49**: 790-794.
- Wang MF Lin HC Wang YY and Hsu CH. 2004a. Treatment of perennial allergic rhinitis with lactic acid bacteria. *Pediatr Allergy Immunol.* **15**: 152-158.
- Wang KY Li SN Liu CS Perng DS Su YC Wu DC Jan CM Lai CH Wang TN and Wang WM. 2004b. Effects of ingesting *Lactobacillus*-and *Bifidobacterium*- containing yoghurt in subjects with colonized *Helicobacter*. *Am J Clin Nutr.* **80**: 737-741.
- Weizman Z Asli G and Alsheikh A. 2005. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. *Pediatrics.* **115**: 5-9.
- Xiao JZ Kondo S Takahashi N Miyaji K Oshida K Hiramatsu A Iwatsuki K Kokubo S and Hosono A. 2003. Effects of milk products fermented by *Bifidobacterium longum* on blood lipids in rats and healthy adult male volunteers. *J Dairy Sci.* **86**: 2452-2461.
- Yateem A Balba MT Al-Surrayai T Al-Mutairi B and Al-Daher R. 2008. Isolation of lactic acid bacteria with probiotic potential from camel milk. *Int. J. Dairy. Sci.* **34**: 194-199.
- Zeng XQ Pan DD and Guo YX 2010. The probiotic properties of *Lactobacillus buchneri* P2. *J. Appl. Microbiol.* **108**: 2059-2066.

